CG Oncology, Inc. Common stock

NASDAQ:CGON

Biotechnology

Healthcare
$80.00 +2.23%

+$1.35 today

Market cap
$7.15B
Beta
0.31
P/E (TTM)
-28.0
EPS (TTM)
-$2.21
52W Low $23.65High $75.50

Volume 1.79M

Average 1.08M

CGON Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

CG Oncology, Inc. Common stockNASDAQ: CGON

Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026

Capital expenditures growth accelerates

Q3 FY2026 capital expenditures of $1.12M (cash outflow) rose 1049.5% year over year, ahead of the +463.7% change in trailing-twelve-month capital expenditures. Sequentially, it rose 138.2% from the prior quarter. Over 3 fiscal years it compounded at +112.3% a year.

Context

  • Capital expenditures amounted to 3.3% of revenue in FY2025, down 17.2 pp from a year earlier.
  • Capital expenditures increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1049.5% holds above the trailing-twelve-month pace of +463.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$1.12M+138.2% QoQ
Last fiscal yearDec 2025
-$134K-42.7% YoY
LTMSep 2026
-$1.89M+463.7% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1049.5%——
1 year-42.7%——
3-year CAGR+112.3%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(134K) USD
Year-over-year change
+42.7%

Capital Expenditures vs competitors

How CGON compares with its peers on the latest reported figures

  • CGON's LTM Sep 2026 capital expenditures of $1.89M is the 2nd largest of the 3 companies compared; the peer median is $4.91M.
  • Its year-over-year change of +463.7% is the highest of 3, against a peer median of +37.7%.
  • Capital expenditures amounts to 30.7% of revenue for CGON, versus a peer median of 2.7%.
CGON Competitors Peer median
Capital Expenditures for CGON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBRXImmunityBio, Inc.LTM Sep 2026$9.53M +87.3%-63.4%5.2%
CGONCG Oncology, Inc. Common stockLTM Sep 2026$1.89M +463.7%+112.3%30.7%
URGNUroGen Pharma Ltd.LTM Mar 2026$299K -11.8%+4.4%0.2%
Peer median (excluding CGON) $4.91M+37.7%-29.5%2.7%

Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Depreciation & Amortization10K15K17K32K1.45M
Deferred Income Tax00000
Stock-Based Compensation1.11M676K1.53M11.4M26.68M
Change in Working Capital(1.97M)4.44M3.44M2.91M2.28M
Accounts Receivables000(689K)(320K)
Inventory0000(444K)
Accounts Payables578K(18K)2.01M3.28M(1.64M)
Other Working Capital(2.55M)4.46M1.43M320K4.68M
Other Non-Cash Items30K509K(2.06M)(5.01M)(1.75M)
Operating Cash Flow(13.65M)(29.8M)(45.68M)(78.71M)(132.35M)
Capital Expenditures(97K)(14K)0(234K)(134K)
Acquisitions (Net)0000(21.97M)
Purchases of Investments0(55.34M)(517.61M)(1.05B)(1.07B)
Sales of Investments00396.42M745.41M844.14M
Other Investing Activities00000
Investing Cash Flow(97K)(55.35M)(121.2M)(300.76M)(245.82M)
Debt Repayment15.2M0(16.29M)(365K)0
Common Stock Issued245K166K2.08M629.47M153.59M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00(3.42M)(825K)0
Financing Cash Flow15.45M119.69M87M628.28M153.59M
Effect of Forex Changes00000
Net Change in Cash1.7M34.54M(79.88M)248.8M(224.58M)
Free Cash Flow(13.75M)(29.82M)(45.68M)(78.95M)(132.48M)

CG Oncology, Inc. Common stock

NASDAQ:CGON

Intrinsic Alpha fair value

Locked

Current Price

$80.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.